UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 8, 2016
CELLDEX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
|
000-15006 |
|
13-3191702 |
|
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
|
of Incorporation) |
|
|
|
Identification No.) |
|
Perryville III Building, 53 Frontage Road, Suite 220, |
|
|
|
Hampton, New Jersey |
|
08827 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (908) 200-7500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders
At the Annual Meeting held on June 8, 2016, our stockholders voted on the three proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 21, 2016 (the “Proxy Statement”). The final results for the votes regarding each proposal are set forth below.
1. Our stockholders elected the following individuals to serve on our board of directors until the annual meeting of stockholders to be held in 2017. The tabulation of votes with respect to the election of such directors was as follows:
|
|
|
For |
|
Withheld |
|
Broker |
|
|
Larry Ellberger |
|
57,428,063 |
|
1,523,132 |
|
26,977,233 |
|
|
Anthony S. Marucci |
|
57,666,935 |
|
1,284,260 |
|
26,977,233 |
|
|
Herbert J. Conrad |
|
57,462,765 |
|
1,488,430 |
|
26,977,233 |
|
|
George O. Elston |
|
57,426,950 |
|
1,524,245 |
|
26,977,233 |
|
|
Harry H. Penner, Jr. |
|
57,420,468 |
|
1,530,727 |
|
26,977,233 |
|
|
Karen L. Shoos |
|
57,657,052 |
|
1,294,143 |
|
26,977,233 |
|
|
Richard A. van den Broek |
|
57,685,933 |
|
1,265,262 |
|
26,977,233 |
|
2. Our stockholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2016. The tabulation of votes with respect to this proposal was as follows:
|
For |
|
Against |
|
Abstain |
|
Broker |
|
|
84,202,598 |
|
1,000,238 |
|
725,592 |
|
— |
|
3. Our stockholders voted to approve, on an advisory, non-binding basis, the compensation for our named executive officers as disclosed in the Proxy Statement. The tabulation of votes with respect to this proposal was as follows:
|
For |
|
Against |
|
Abstain |
|
Broker |
|
|
56,600,834 |
|
1,638,604 |
|
711,757 |
|
26,977,233 |
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CELLDEX THERAPEUTICS, INC. | |
|
|
| |
|
|
| |
|
|
By: |
/s/ Avery W. Catlin |
|
|
|
Name: Avery W. Catlin |
|
|
|
Title: Senior Vice President / Chief Financial Officer |
Dated: June 9, 2016